

Cellectra™ Human TCRαβ NanoDeplet Microbeads, Research grade

Cat. No. MBS-S011

● Product Information

Product	Size	Amount
Cellectra™ Human TCRαβ NanoDeplet Microbeads, Research grade	2 mL	For 10 ⁹ total cells

● Product Description

Cellectra™ Human TCRαβ NanoDeplet Microbeads, Research grade are dextran-coated superparamagnetic iron oxide nanoparticles of which the surface is conjugated with recombinant monoclonal antibodies specific to human TCRαβ (Isotype: mouse IgG1). They are especially designed for the depletion of TCRαβ⁺ cells.

Cellectra™ Human TCRαβ NanoDeplet Microbeads, Research grade are produced under sterile manufacturing conditions (ISO 5), and no animal- or human-derived components are used throughout the production process. It is produced under our rigorous quality control system that includes a comprehensive set of tests including sterility and endotoxin tests.

● Product Applications

Cellectra™ Human TCRαβ NanoDeplet Microbeads, Research grade are designed for the depletion of TCRαβ⁺ cells from fresh or frozen human peripheral blood mononuclear cells (PBMCs) and cord blood mononuclear cells (CBMCs) or other cell products. TCRαβ represents the hallmark receptor complex on nearly all adaptive CD4 helper and CD8 cytotoxic T cells, and functions as the primary effector marker driving graft-versus-host disease (GVHD) and allogeneic rejection. Conventional CD3 depletion reagents remove all T cell subsets indiscriminately. In contrast, this microbead product enables targeted elimination of solely TCRαβ⁺ adaptive T cells, completely retaining intact populations of γδ T cells, NK cells, B cells, monocytes and dendritic cells for unconfounded innate immune research. The magnetic Microbeads are conjugated with monoclonal antibodies targeting human TCRαβ protein, enabling TCRαβ⁺ cells to be labeled with the specific antibodies and magnetic particles, and separated using the separation columns and magnets.

The Product performance has been carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage. For use in clinical phases, we also offer a custom GMP production service that tailors to your needs. We will work with you to customize and develop a GMP-grade product in accordance with your requests that also meets the requirements for raw and ancillary materials use in cell manufacturing of cell-based therapies.

● Formulation

Supplied in PBS buffer containing EDTA, rHSA and Poloxamer 188.

● Storage

For long term storage, the product should be stored in liquid state at -20°C or below

Stability upon receipt:

- Stable for 12 months at -20 °C or below;
- Stable for 3 months at 2–8 °C under sterile conditions.

Please protect from light and avoid repeated freeze-thaw cycles.


● Important Note

This product is for research use only and not intended for therapeutic or diagnostic use.

Workflow of Separation of Cells using Celectra NanoDeplet Microbeads


Label the cells

- Prepare cell suspension at 1.25×10^8 cells/mL in Isolation Buffer
- Add 20 μ L Microbeads per 1×10^7 cells, incubate 15 min
- Remove excessive Microbeads by centrifugation



Magnetic Separation

- Place a separation column into a compatible magnet
- Rinse the column with Isolation Buffer to obtain the target cells
- Unwanted cells are retained in the column and depleted



● General guidelines

Required Materials

- Isolation Buffer: Prepare a solution containing phosphate-buffered saline (PBS), pH 7.2, 0.5% BSA, and 2 mM EDTA and keep it cold (2–8°C).

Note: BSA can be replaced by other proteins such as human serum albumin, human serum, or fetal bovine serum (FBS). EDTA can be replaced by sodium citrate. PBS containing Ca^{2+} or Mg^{2+} is not recommended.

- Separation Column: MS/LS/LD separation columns or equivalent performance from other suppliers are acceptable as alternatives.
- Use LD columns if higher depletion efficiency is required, resulting in high target cell purity.
- Reduce Microbeads dosage accordingly if better recovery of target cells is desired.
- Magnetic Separators compatible to LS, MS and LD column, or equivalent performance from other suppliers are acceptable as alternatives.

PBMC Preparation

1. Prepare a single-cell suspension of human PBMCs at the concentration of 1.25×10^8 cells/mL in Isolation Buffer.

Note: a. For anticoagulated blood: Isolate PBMCs using Ficoll-Paque™ density gradient centrifugation.

b. For frozen PBMCs: Thaw and remove dead cells via Ficoll-Paque™ density gradient centrifugation.

c. Wash all PBMCs with Isolation Buffer (300×g, 10 min, 15–25 °C) before suspension preparation.

Magnetic labeling

2. Transfer the required volume of PBMC single-cell suspension (1.25×10^8 cells/mL in Isolation Buffer) into a new tube.
3. Add 20 μ L Microbeads for every 10^7 PBMCs suspended in 80 μ L buffer, to a total volume of 100 μ L for incubation.

Note: Scale Microbeads volume proportionally for higher cell counts (e.g., 40 μ L Microbeads for 2×10^7 PBMCs in a total incubation volume of 200 μ L).

4. Mix the cell-bead mixture by gently pipetting up and down, and incubate for 15 min at 2~8 °C.
5. Add 400 µL of isolation buffer, centrifuge at 300×g for 10 minutes at room temperature, and carefully aspirate the supernatant.
6. Repeat washing *step 5*.
7. Centrifuge at 300×g for 10 minutes, and then remove the supernatant completely.
8. Resuspend the cells in 500 µL Isolation Buffer per 1×10⁷ cells for separation.


Magnetic separation

9. Place MS column in the magnetic field of a separator.
10. Prepare the separation column by rinsing it with 1000 µL of Isolation Buffer.
11. Apply cell suspension to primed the separation column, and collect the flow-through containing unlabeled cells.
12. Wash the separation column with 500 µL of Isolation Buffer twice, and collect the flow-through containing unlabeled cells.
13. Pool the flow-through fractions collected from *step11* and *step12*, these fractions contain target cells.

Note: To increase the purity of TCRαβ⁺ cells, the flow-through can be enriched over a second MS column. Repeat the magnetic separation procedure as described by using a new column.

14. Analyze the fractions to assess the purity or used in down-stream applications.

● Example of a separation



Percentage of TCRαβ⁺ cells pre- and post-depletion with Collectra™ Human TCRαβ NanoDeplet Microbeads, Research Grade.

Human PBMCs (per 10⁷ cells) were isolated by 20 µL Collectra™ Human TCRαβ NanoDeplet Microbeads, Research grade (Cat. No. MBS-S011). The non-isolated flow cells were stained with FITC-anti human TCRαβ Antibody, PE-anti human CD3 Antibody and 7-AAD, and subsequently analyzed by flow cytometry (QC tested).

● Disclaimer

Any third-party trademarks, product names, and catalog numbers referenced in this document are included solely for descriptive purposes—to illustrate proper operation and identify compatible consumables, reagents, and instruments. ACRO assumes no liability for risks arising from the use of third-party products and disclaims all warranties, express or implied, regarding their quality, performance, or reliability.

